Grey Wolf Therapeutics raised 46 million Euros to treat Autoimmune disease

Grey Wolf Therapeutics is a clinical-stage biotech company that leverages first-of-its-kind antigen modulation therapy to correct immune dysfunction in oncology and autoimmunity. According to the reports, the company has announced the closing of an oversubscribed €46 million series B financing expansion, thus bringing the total Series B funds raised to $99 million. 

The team of ICG Life Sciences led the series B expansion round. It included further investments from the existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital. The proceeds from the round will be utilised to broaden the scope of the company’s ongoing Phase1/2 clinical trial of GRWD5769, the leading immuno-oncology candidate. 

The funding encourages Grey Wolf Therapeutics to expand its R&D for its versatile antigen modulation approach to treatment for autoimmune disease indications. 

 The CEO, Peter Joyce, Ph.D., says, “The funds raised as part of this Series B expansion round allows us to enrich our ongoing clinical trial of GRWD5769 to include patients with a wider variety of tumour types and evaluate new combination treatment cohorts. In addition, the new capital enables us to more fully explore the breadth of potential therapeutic applications for our antigen modulation technology,”

 said Peter Joyce, Ph.D., chief executive officer of Grey Wolf Therapeutics. 

“There is a wealth of supportive recent clinical research and compelling human genetic associations pointing to the potential for antigen modulation driven by ERAP inhibition to open the door for disease-modifying therapies in the field of autoimmune disease. As such, we are expanding our R&D efforts and evaluating these broader therapeutic applications for our unique technology.”

The initial data on the ongoing adaptive Phase1/2 trial of GRWD5769, a first-in-class ERAP1 inhibitor, will be shared at the American Society of Clinical Oncology’s annual meeting in 2024.